Cargando…

Efficacy of erlotinib and celecoxib for patients with advanced non-small cell lung cancer: A retrospective study

This study evaluated the efficacy and toxicity of erlotinib and celecoxib (EC) for treating Chinese patients with advanced non-small cell lung cancer (ANSCLC) and epidermal growth factor receptor (EGFR) wild type. Totally, 75 subjects with ANSCLC and EGFR wild type were included. They all underwent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jin, Yi-Hua, Li, Wei-Hong, Bai, Yan, Ni, Lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417627/ https://www.ncbi.nlm.nih.gov/pubmed/30855490 http://dx.doi.org/10.1097/MD.0000000000014785

Ejemplares similares

Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients
por: Xiong, Liwen, et al.
Publicado: (2019)

Review of erlotinib in the treatment of advanced non-small cell lung cancer
por: Ganjoo, Kristen N, et al.
Publicado: (2007)

Systematic review and meta-analysis of the benefit of celecoxib in treating advanced non-small-cell lung cancer
por: Yi, Lilan, et al.
Publicado: (2018)

Meta-analysis of efficacy and adverse events of erlotinib-based targeted therapies for advanced/metastatic non-small cell lung cancer
por: Li, Fei, et al.
Publicado: (2017)

Comparing Efficacy of Erlotinib and Bevacizumab Combination with Erlotinib Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis
por: Sakharkar, Prashant, et al.
Publicado: (2023)

Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study
por: Emery, Ivette F, et al.
Publicado: (2009)

Observational study on the efficacy and safety of erlotinib in patients with non-small cell lung cancer
por: KABURAGI, TAKAYUKI, et al.
Publicado: (2013)

A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib, and Afatinib in Japanese Patients With Non-Small Cell Lung Cancer
por: Fujiwara, Atsushi, et al.
Publicado: (2018)

Comparison of the benefits of celecoxib combined with anticancer therapy in advanced non-small cell lung cancer: A meta-analysis
por: Zhang, Wei, et al.
Publicado: (2020)

Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
por: Kim, Youjin, et al.
Publicado: (2019)

Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer
por: Reguart, Noemí, et al.
Publicado: (2010)

Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib
por: Melosky, B., et al.
Publicado: (2008)

Inhibition of mitochondrial glutaminase activity reverses acquired erlotinib resistance in non-small cell lung cancer
por: Xie, Caifeng, et al.
Publicado: (2015)

Genetic Association of Drug Response to Erlotinib in Chinese Advanced Non-small Cell Lung Cancer Patients
por: Wang, Cong, et al.
Publicado: (2018)

Bowel Perforation after Erlotinib Treatment in a Patient with Non-Small Cell Lung Cancer
por: Cheon, Yun-Hong, et al.
Publicado: (2011)

Erlotinib-based doublet targeted therapy versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis from 24 randomized controlled trials
por: Gao, Jian-Wei, et al.
Publicado: (2017)

Identifying erlotinib-sensitive non-small cell lung carcinoma tumors in mice using [(11)C]erlotinib PET
por: Abourbeh, Galith, et al.
Publicado: (2015)

Erlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer
por: Mita, A C, et al.
Publicado: (2011)

Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
por: Li, Ruijian, et al.
Publicado: (2023)

Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis
por: Zhang, Shu, et al.
Publicado: (2016)

Scalable Production and In Vitro Efficacy of Inhaled Erlotinib Nanoemulsion for Enhanced Efficacy in Non-Small Cell Lung Cancer (NSCLC)
por: Chauhan, Gautam, et al.
Publicado: (2023)

Efficacy and safety of erlotinib combined with bevacizumab in the treatment of non-small cell lung cancer: A systematic review and meta-analysis
por: Zhou, Kenan, et al.
Publicado: (2020)

Role of erlotinib in the targeted treatment of non-small-cell lung cancer in Chinese patients
por: Li, Wei, et al.
Publicado: (2014)

Curcumol potentiates celecoxib-induced growth inhibition and apoptosis in human non-small cell lung cancer
por: Cai, Fangfang, et al.
Publicado: (2017)

Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy
por: Khan, Iftekhar, et al.
Publicado: (2015)

Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment
por: Jakobsen, Jan Nyrop, et al.
Publicado: (2018)

A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations
por: Yang, J J, et al.
Publicado: (2017)

YAP promotes erlotinib resistance in human non-small cell lung cancer cells
por: Hsu, Ping-Chih, et al.
Publicado: (2016)

Combining Whole-Brain Radiotherapy with Gefitinib/Erlotinib for Brain Metastases from Non-Small-Cell Lung Cancer: A Meta-Analysis
por: Zheng, Mao-hua, et al.
Publicado: (2016)

Chemotherapy plus Erlotinib versus Chemotherapy Alone for Treating Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
por: Xu, J. L., et al.
Publicado: (2015)

Metformin Synergistically Enhanced the Antitumor Activity of Celecoxib in Human Non-Small Cell Lung Cancer Cells
por: Cao, Nini, et al.
Publicado: (2020)

Gefitinib or Erlotinib as Maintenance Therapy in Patients with Advanced Stage Non-Small Cell Lung Cancer: A Systematic Review
por: Chen, Xiaofeng, et al.
Publicado: (2013)

Second- and Further-Line Therapy with Erlotinib in Patients with Advanced Non-Small-Cell Lung Cancer in Daily Clinical Practice
por: Krainhöfer, Josephine, et al.
Publicado: (2014)

Erlotinib in salvage treatment of patients with advanced non-small cell lung cancer: results of an expanded access programme in Poland
por: Kowalski, Dariusz M., et al.
Publicado: (2012)

Erlotinib-Associated Rash in Advanced Non-Small Cell Lung Cancer: Relation to Clinicopathological Characteristics, Treatment Response, and Survival
por: Kainis, Ilias, et al.
Publicado: (2018)

Evaluation of Erlotinib in Advanced Non-Small Cell Lung Cancer: Impact on the Budget of a U.S. Health Insurance Plan
por: Ramsey, Scott D., et al.
Publicado: (2006)

Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure
por: Cho, Kyoung Min, et al.
Publicado: (2015)

Efficacy and dose of afatinib in patients with non‐small cell lung cancer after failure of prior gefitinib or erlotinib treatment
por: Choi, Hayoung, et al.
Publicado: (2021)

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomised controlled trials
por: Deng, Wusheng, et al.
Publicado: (2022)

Gefitinib provides similar effectiveness and improved safety than erlotinib for advanced non-small cell lung cancer: A meta-analysis
por: Zhang, Wenxiong, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4sohjb49f0b1q7e4sn1hs8duui